Exact Sciences Corp. Proxy Filing
Ticker: EXAS · Form: DEFA14A · Filed: 2025-11-24T00:00:00.000Z
Sentiment: neutral
Topics: proxy, filing, employee-communication
Related Tickers: EXAS
TL;DR
EXAS filed proxy docs for employee email from CEO Conroy on Nov 21. No fee.
AI Summary
Exact Sciences Corp. filed a DEFA14A on November 24, 2025, related to soliciting material sent to employees on November 21, 2025. The email, from Kevin Conroy, was a follow-up communication to the team. The filing indicates no fee was required for this submission.
Why It Matters
This filing provides insight into Exact Sciences Corporation's communications with its employees regarding company matters, which can be relevant for understanding internal corporate governance and employee engagement.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement related to employee communications and does not appear to contain significant new financial or strategic information that would immediately impact the stock price.
Key Players & Entities
- EXACT SCIENCES CORP (company) — Registrant
- Kevin Conroy (person) — Sender of employee email
- November 21, 2025 (date) — Date of employee email
- November 24, 2025 (date) — Filing date
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which is a Schedule 14A Information Proxy Statement.
Who is the filing company?
The filing company is EXACT SCIENCES CORP.
When was this filing submitted?
The filing was submitted on November 24, 2025.
What was the subject of the communication mentioned in the filing?
The filing references an email sent to employees on November 21, 2025, from Kevin Conroy, with the subject 'Following up'.
Was there a fee required for this filing?
No fee was required for this filing.
From the Filing
0001193125-25-291700.txt : 20251124 0001193125-25-291700.hdr.sgml : 20251124 20251121185603 ACCESSION NUMBER: 0001193125-25-291700 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20251124 DATE AS OF CHANGE: 20251121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EXACT SCIENCES CORP CENTRAL INDEX KEY: 0001124140 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 200478229 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-35092 FILM NUMBER: 251509300 BUSINESS ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 BUSINESS PHONE: 608-284-5700 MAIL ADDRESS: STREET 1: 5505 ENDEAVOR LANE CITY: MADISON STATE: WI ZIP: 53719 FORMER COMPANY: FORMER CONFORMED NAME: EXACT CORP DATE OF NAME CHANGE: 20000919 DEFA14A 1 d82308ddefa14a.htm DEFA14A DEFA14A Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under §240.14a-12 EXACT SCIENCES CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 The following email was sent to employees of Exact Sciences Corporation on the evening of November 21, 2025. Kevin Conroy all team email Date : November 21, 2025 Subject : Following up on yesterday BCC : DL Employees Exact Sciences; DL Remote Employees Exact Sciences Team, Yesterday was a meaningful and inspiring day for Exact Sciences. We announced our agreement to be acquired by Abbott, a milestone that celebrates the extraordinary work of this team and opens a new chapter filled with opportunity. I feel deep pride in what we’ve built together and excitement for what lies ahead. We will move forward with care for our people, transparency in our process, and focus on our mission. Joining Abbott allows us to reach more patients, faster. Their scale and global resources will help us prevent cancer, detect it earlier, and guide treatment for many more people. I also want to thank Robert Ford for visiting Madison yesterday. Hearing directly from him showed how closely our values and purpose connect, as well as the strength of what we can achieve together. As we take this next step, it’s important to remember that we will operate as an independent company until the transaction closes, which is expected sometime in Q2. During this time, please do not reach out directly to people at Abbott unless a member of the integration team, which we’ll be forming shortly, has asked you to do so. It is critical that we stay focused on our mission and our goals. Here’s my ask for you now: 1. Visit our Nucleus page for the latest updates and materials. 2. Read the FAQs so you have the facts and know where to go with questions. 3. If you cannot find something, notify your manager or HR. 4. Join any upcoming employee town halls and team sessions. Leaders will walk through details and take questions. I will also join several of these. I promise to keep sharing timely, honest updates as we confirm them. You’ll hear more about what’s next after the Thanksgiving holiday. For now, I hope you take time to rest, recharge, and enjoy moments with your loved ones. On a personal note, I’ve dedicated many years to working at this incredibl